Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New CDRH Decision Methods Will Be Put To The Test, Starting With Stents

This article was originally published in The Gray Sheet

Executive Summary

Defining a "new science" for post-market surveillance is a top priority for the FDA device center's post-market group, according to the program's new leader
Advertisement

Related Content

Parting Words: Larry Kessler Urges CDRH To Put Science Over Clinical Hopes
Parting Words: Larry Kessler Urges CDRH To Put Science Over Clinical Hopes
People In Brief
People In Brief
Reimbursement, Not Off-Label Use, May Be Hindering Carotid Stent Trials
Postmarket Transformation Plan Update With FDA’s Don St. Pierre
Advertisement
UsernamePublicRestriction

Register

MT026622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel